Kou Chung-Ting J, Romain Joshua, Broadwater Devin R, Barnett Taylor
Internal Medicine, Brooke Army Medical Center, Fort Sam Houston, USA.
Hematology and Oncology, Brooke Army Medical Center, Fort Sam Houston, USA.
Cureus. 2020 Dec 16;12(12):e12112. doi: 10.7759/cureus.12112.
Multiple myeloma (MM) is a malignancy of plasma cells characterized by the clonal proliferation of plasma cells that produce monoclonal immunoglobulins. While typically considered to be incurable, advances in treatment options have led to remarkable improvements in survival for these patients. Accumulating evidence suggests an increased risk for the development of a secondary primary malignancy (SPM) in these patients, perhaps as a result of myeloma directed therapy or as an effect of their underlying disease process. Here we present a case of a patient who was diagnosed with an SPM while undergoing palliative treatment for multiple myeloma and a treatment approach.
多发性骨髓瘤（MM）是一种浆细胞恶性肿瘤，其特征是产生单克隆免疫球蛋白的浆细胞发生克隆性增殖。虽然通常被认为是无法治愈的，但治疗方案的进展已使这些患者的生存率有了显著提高。越来越多的证据表明，这些患者发生继发性原发性恶性肿瘤（SPM）的风险增加，这可能是骨髓瘤定向治疗的结果，也可能是其潜在疾病过程的影响。在此，我们介绍一例在接受多发性骨髓瘤姑息治疗时被诊断出患有SPM的患者及一种治疗方法。
